How to Diagnose BPH
The diagnosis of BPH in men over 50 with lower urinary tract symptoms requires a structured initial work-up including medical history with symptom assessment using the International Prostate Symptom Score (IPSS), physical examination with digital rectal exam, urinalysis, and serum PSA measurement 1.
Initial Mandatory Assessment (Primary Care Level)
The following components form the foundation of BPH diagnosis 1, 2:
Medical history focusing on:
- Voiding symptoms (hesitancy, weak stream, straining, prolonged voiding)
- Storage symptoms (frequency, urgency, nocturia, urge incontinence)
- Post-void symptoms (dribbling, incomplete emptying)
- Degree of bother and impact on quality of life
IPSS questionnaire - This validated tool quantifies symptom severity and should be used both for initial diagnosis and monitoring treatment response 3, 2. Moderate symptoms are defined as IPSS ≥8 with moderate bother ≥3 on the bothersome index question 4.
Physical examination - Digital rectal exam to assess prostate size, consistency, and rule out nodules suggestive of malignancy 1.
Urinalysis - To exclude urinary tract infection, hematuria, or other pathology 2.
Serum PSA measurement - Essential for risk stratification and ruling out prostate cancer. A PSA >1.5 ng/mL combined with prostate volume >30cc indicates higher risk of progression and suggests need for more aggressive therapy 4, 5.
Additional Urologic Assessment
When patients are referred to urology or require more detailed evaluation, the following are mandatory 2:
- Uroflowmetry - Objective measurement of urinary flow rate
- Post-void residual (PVR) measurement - Assesses bladder emptying efficiency 3
- Prostate ultrasonography - Determines prostate volume, which is critical for treatment selection. Prostates >30cc benefit from 5-alpha reductase inhibitor therapy 1, 4
Critical Diagnostic Considerations
Nocturia requires special attention as it may result from nocturnal polyuria or sleep disturbance rather than BPH itself 2. This is a common pitfall - don't automatically attribute all nocturia to prostatic obstruction.
The 2021 AUA guidelines emphasize that BPH is technically a histologic diagnosis referring to proliferation of glandular epithelial tissue, smooth muscle, and connective tissue in the prostatic transition zone 1. However, clinically we diagnose based on the constellation of benign prostatic enlargement (BPE) causing benign prostatic obstruction (BPO) manifesting as LUTS.
What to Rule Out
Before confirming BPH diagnosis, exclude 5:
- Prostate cancer (via PSA and DRE)
- Bladder cancer (especially if hematuria present)
- Urethral stricture
- Neurogenic bladder
- Urinary tract infection
Diagnostic Algorithm Summary
- Screen with IPSS - If ≥8 with bother ≥3, proceed
- Perform DRE and obtain PSA - Rule out cancer
- Urinalysis - Rule out infection/hematuria
- Measure prostate size (ultrasound if available) - Determines treatment strategy
- Assess PVR and flow rate (urologic setting) - Quantifies obstruction
The strength of this diagnostic approach is supported by high-quality guideline evidence from both the 2021 AUA guidelines 1 and 2023 EAU guidelines 6, with consistent recommendations across international societies 2.